Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial (Q58051900)
Jump to navigation
Jump to search
article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial |
article |
Statements
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial (English)
Françoise Kraeber-Bodéré
Caroline Rousseau
Caroline Bodet-Milin
Ludovic Ferrer
Alain Faivre-Chauvet
Jean-Philippe Vuillez
Anne Devillers
Chien-Hsing Chang
David M Goldenberg
Jean-François Chatal